Karyopharm Therapeutics INC ( (KPTI) ) has released its Q4 earnings. Here is a breakdown of the information Karyopharm Therapeutics INC presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, is pioneering novel cancer therapies and is known for its focus on the development and commercialization of oral compounds that address nuclear export dysregulation.
Karyopharm’s latest financial report for 2024 highlights a total revenue of $145 million, with U.S. XPOVIO net product revenue reaching $113 million. The company anticipates top-line data from its Phase 3 SENTRY trial in myelofibrosis by the second half of 2025, while updates to its Phase 3 XPORT-EC-042 trial in endometrial cancer are expected to yield results by mid-2026.
Key financial metrics reveal a slight decline in total revenue compared to the previous year, while net product revenue showed a modest increase. The company expanded global access for selinexor with favorable reimbursement decisions across several countries. Research and development expenses increased due to heightened clinical trial activity, although selling, general, and administrative expenses decreased owing to cost optimization efforts.
Looking ahead, Karyopharm projects 2025 total revenue to range between $140 million and $155 million, with a focus on advancing its clinical trials and maintaining its commercial foundation in the competitive multiple myeloma market. The company remains optimistic about its ability to fund operations into 2026, supported by existing cash reserves and anticipated revenue.
